CGON
$65.08-0.78 (-1.18%)
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
Recent News
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Is CG Oncology (CGON) Pricing Reflect Its Recent 131% Surge And Cancer Breakthrough Hopes
If you are wondering whether CG Oncology's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for this stock. Over the past week the share price return was 3.9%, over the last month it was 20.1%, year to date it was 53.8%, and over the past year it was 131.3%, which naturally raises questions about what is already baked into the current US$64.29 price. Recent news coverage has focused on CG Oncology as a cancer focused biotech name,...
CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026
Executives from CG Oncology (NASDAQ:CGON) outlined clinical results, ongoing trials, and launch preparations for its investigational intravesical therapy cretostimogene (referred to as “Credo”) during a recent company event, emphasizing response durability in high-risk non–muscle invasive bladder ca
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating
CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, H.C. Wainwright raised the firm’s price target on CG Oncology, Inc. (NASDAQ:CGON) to $80 from $75 and maintained a Buy rating on the shares. The analyst said the company is advancing toward a biologics application submission for […]
Company News for Mar 2, 2026
Companies in The News Are: BCS, XYZ, INTU, CGON